These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31940465)

  • 41. Etanercept for the treatment of hidradenitis suppurativa.
    Sotiriou E; Apalla Z; Ioannidos D
    Acta Derm Venereol; 2009; 89(1):82-3. PubMed ID: 19197548
    [No Abstract]   [Full Text] [Related]  

  • 42. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer.
    Bordignon V; Bultrini S; Prignano G; Sperduti I; Piperno G; Bonifati C; Filippetti M; Toma L; Latini A; Di Cecio M; Giuliani A; Vocaturo A; Trento E; D' Agosto G; Francesconi F; Cataldo A; Vento A; Cilenti V; Berardesca E; Ameglio F; Cordiali Fei P; Ensoli F
    J Biol Regul Homeost Agents; 2011; 25(2):213-20. PubMed ID: 21880210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Testing for latent tuberculosis infection using interferon gamma release assays in commercial sex workers at an outreach clinic in Birmingham.
    Daly R; Khatib N; Larkins A; Dedicoat M
    Int J STD AIDS; 2016 Jul; 27(8):676-9. PubMed ID: 26589629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
    Sbidian E; Hotz C; Seneschal J; Maruani A; Amelot F; Aubin F; Paul C; Beylot Barry M; Humbert P; Dupuy A; Caux F; Dupin N; Modiano P; Lepesant P; Ingen-Housz-Oro S; Mahé E; Bachelez H; Chosidow O; Wolkenstein P
    Br J Dermatol; 2016 Mar; 174(3):667-70. PubMed ID: 26406350
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa.
    Balato A; Caiazzo G; Annunziata MC; Marasca C; Scala E; Cacciapuoti S; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):e43-e45. PubMed ID: 29956847
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of moderate to severe hidradenitis suppurativa.
    Kimball AB; Gu Y; Okun M
    Ann Intern Med; 2013 Jul; 159(1):72-3. PubMed ID: 23817710
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of moderate to severe hidradenitis suppurativa.
    Prasad V
    Ann Intern Med; 2013 Jul; 159(1):72. PubMed ID: 23817709
    [No Abstract]   [Full Text] [Related]  

  • 50. PpiA antigen specific immune response is a potential biomarker for latent tuberculosis infection.
    Pathakumari B; Anbarasu D; Parthasarathy RT; Raja A
    Tuberculosis (Edinb); 2015 Dec; 95(6):736-743. PubMed ID: 26546406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
    Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
    BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 53. Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?
    Johnson MG; Bialas RW; Hall RP; Stout JE
    J Dermatolog Treat; 2016 Aug; 27(4):378-80. PubMed ID: 26652171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
    Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
    [No Abstract]   [Full Text] [Related]  

  • 55. Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa.
    Bettuzzi T; Frumholtz L; Jachiet M; Lepelletier C; Djermane M; Cordoliani F; Saussine A; Bouaziz JD; Bachelez H
    J Am Acad Dermatol; 2020 Nov; 83(5):1441-1444. PubMed ID: 32565204
    [No Abstract]   [Full Text] [Related]  

  • 56. Estimating Latent Tuberculosis Infection Using Interferon-γ Release Assay, Japan.
    Nishimura T; Ota M; Mori M; Hasegawa N; Kawabe H; Kato S
    Emerg Infect Dis; 2018 Nov; 24(11):2111-2113. PubMed ID: 30334726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.
    Brunasso AM; Massone C
    Eur J Dermatol; 2010; 20(5):644-6. PubMed ID: 20615818
    [No Abstract]   [Full Text] [Related]  

  • 59. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
    Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
    J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
    [No Abstract]   [Full Text] [Related]  

  • 60. Combined IFN-γ and TNF-α release assay for differentiating active tuberculosis from latent tuberculosis infection.
    Kim JY; Park JH; Kim MC; Cha HH; Jeon NY; Park SY; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH
    J Infect; 2018 Oct; 77(4):314-320. PubMed ID: 29746954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.